Celltrion Presents One Year Results of Yuflyma (biosimilar, adalimumab) in P-III CT-P17 3.1 Trial for Rheumatoid Arthritis at EULAR 2021

June 3, 2021 Auto Bot Biosimilar, Biosimilars, Clinical Trials, P-III, rheumatoid arthritis 0

Shots:

  • The P-III CT-P17 3.1 trial involves assessing Yuflyma (adalimumab, 40mg, high-concentration formulation, low-volume and citrate-free, q2w, up to 24 wks.) vs reference adalimumab in a ratio (1:1) in 648 patients with active RA
  • The one year data demonstrated comparable efficacy of Yuflyma to reference adalimumab in terms of ACR20/50/70 response rates in patients receiving maintenance therapy and who switched from reference adalimumab to CT-P17 @26wks. up to 52wks., ADA and NAb results were also similar in three treatment groups
  • Additionally, EC has granted marketing authorization for Remsima SC (infliximab) to be used without IV infusion for RA patients

Click here to­ read full press release/ article | Ref: Businesswire | Image: Pulse News Korea

The post Celltrion Presents One Year Results of Yuflyma (biosimilar, adalimumab) in P-III CT-P17 3.1 Trial for Rheumatoid Arthritis at EULAR 2021 first appeared on PharmaShots.